Company news

Vanda Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021

October 26, 2021

Vanda Pharmaceuticals Announces Participation at Evercore ISI's Catalyst Day

October 13, 2021

Vanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference

September 6, 2021

Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients

August 2, 2021

Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results

July 27, 2021

Vanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021

July 20, 2021

Vanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences

May 11, 2021

Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results

May 4, 2021

Vanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021

April 19, 2021

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 9, 2021

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021

February 1, 2021

FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

November 30, 2020

Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results

October 27, 2020

Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis

October 25, 2020

Vanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020

October 20, 2020

Vanda Pharmaceuticals Provides Update on Tradipitant Development Program

August 30, 2020

Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia

August 17, 2020

Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results

August 4, 2020

FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome

August 2, 2020

Vanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020

July 28, 2020

FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis

July 12, 2020

Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting

May 25, 2020

Vanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit

May 19, 2020

Vanda Pharmaceuticals CEO's Proposal on Clinical Trial Data Sharing, COVID-19 and Remdesivir

May 19, 2020

Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome

May 12, 2020

Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

May 5, 2020

Vanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020

April 28, 2020

Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia

April 14, 2020

Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine

April 14, 2020

Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19

April 7, 2020

Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia

April 1, 2020

Vanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences

February 26, 2020

Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis

February 24, 2020

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

February 24, 2020

Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors

February 18, 2020

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020

February 17, 2020

Vanda Pharmaceuticals Comments on Court Ruling

January 30, 2020

Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

January 12, 2020

Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

November 17, 2019

Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 5, 2019

Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

October 29, 2019

Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors

October 27, 2019

Vanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs

October 22, 2019

Vanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement

October 15, 2019

Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

September 10, 2019

Vanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer

August 20, 2019

Vanda Pharmaceuticals FDA Update for HETLIOZ® in the Treatment of Jet Lag Disorder

August 18, 2019

Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results

July 30, 2019

Vanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019

July 21, 2019

Tradipitant Effective in Preventing Motion Sickness

July 15, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.